Quanterix Corporation QTRX Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

RevvityRVTY

——

Pacific Biosciences of CaliforniaPACB

——

Simulations PlusSLP

——

VeracyteVCYT

——

Other financials

Income statement

See full

Revenue$36.4M+20.1%

Gross profit$15.6M+4.9%

Operating income-$41.4M-56.9%

Net income-$17.5M+14.5%

EPS (diluted)-$0.37+30.2%

Balance sheet

See full

Cash & equivalents$36.2M-52.7%

Total debt$35.3M-2.9%

Total equity$282.1M-10.8%

Total assets$366.7M-7.5%

Cash flow

See full

Operating cash flow-$18.1M-30.4%

CapEx$87.0K-93.1%

Free cash flow-$18.2M-20.1%

Valuation

See full

Market cap$203.97M-20.1%

Enterprise value$203.12M+28.6%

P/S1.4×-0.6×

Profitability

See full

Gross margin44.2%-14.3pp

Operating margin-96.9%-1,691pp

Net margin-71.9%-2,019pp

FCF margin-57.2%-220pp

Returns & leverage

See full

Return on equity-34.8%-122pp

Debt / equity0.1×0.0×

Current ratio3.7×-4.6×

Where this comes from

Reported directly by Quanterix Corporation in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Quanterix Corporation’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Quanterix Corporation's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Quanterix Corporation's contingent consideration fair value adjustments?: Quanterix Corporation (QTRX) reported contingent consideration fair value adjustments of -$1.5M in Q1 2026.
How has Quanterix Corporation's contingent consideration fair value adjustments changed year-over-year?: Quanterix Corporation's contingent consideration fair value adjustments decreased by 496.0% year-over-year, from $379K to -$1.5M.